证券代码：688410 证券简称：山外山 公告编号：2023-059 重庆山外山血液净化技术股份有限公司 关于参加 2023 年半年度医疗器械及医疗设备行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 9 月 1 日(星期五)16:00 前通过邮件、电话、传真等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍 关注的问题进行回答。 重庆山外山血液净化技术股份有限公司（以下简称"公司"）已于 2023 年 8 月 28 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公 司 2023 年半年度经营成果、财务状况、发展理念，公司参与了由上海证券交所 所主办的 2023 年半年度医疗器械及医疗设备行业集体业绩说明会，此次活动将 采用视频和网络文字互动的方式举行，投资者可登录上海证券交易所上证路演中 心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资者说明会以视频和 ...

Financial Performance - The company achieved operating revenue of CNY 394,679,456.40 in the first half of 2023, representing a 157.13% increase compared to the same period last year[20]. - Net profit attributable to shareholders reached CNY 134,240,442.45, marking a significant increase of 687.10% year-on-year[20]. - The net profit after deducting non-recurring gains and losses was CNY 128,885,687.89, up 838.66% from the previous year[20]. - Basic earnings per share rose to CNY 0.9275, reflecting a 490.39% increase compared to the same period last year[21]. - The company's total assets at the end of the reporting period were CNY 1,988,501,723.83, an increase of 3.37% from the end of the previous year[20]. - The company's net assets attributable to shareholders increased to CNY 1,650,092,685.28, an 8.95% rise from the previous year-end[20]. - The company reported a total revenue of RMB 6,120.05 million and a net profit of RMB 143.19 million for the first half of 2023[122]. - The company reported a negative gross margin for self-produced consumables, which may adversely affect revenue and profit growth if high-value consumables do not achieve timely production and sales[102]. Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.00 per 10 shares, totaling RMB 28,946,051.80, which represents 21.56% of the net profit attributable to shareholders for the first half of 2023[3]. - The company intends to increase its share capital by 4.9 shares for every 10 shares held, resulting in an increase of total shares to 215,648,085 after the capital increase[126]. - The company's financial performance indicates a focus on maintaining shareholder returns through dividends and capital increases[127]. - The company’s operational strategy includes potential adjustments to dividend distribution based on changes in total share capital[127]. Research and Development - The company reported a total of 14,586,903.93 CNY in research and development (R&D) expenses, representing a 39.28% increase compared to the same period last year[72]. - The total R&D investment amounted to 14,949,111.86 CNY, which is an 18.09% increase year-on-year[73]. - The proportion of R&D expenses to operating income decreased to 3.79%, down from 8.25% in the previous year, indicating a significant reduction in R&D relative to revenue[73]. - The number of R&D personnel increased to 122, representing 14.24% of the total workforce, compared to 83 and 12.41% in the previous year[79]. - The company is currently working on several projects, including the SWS-2000A blood perfusion machine, with an expected total investment of 400.00 million CNY[75]. - The company has developed a new type of blood purification device that integrates multiple treatment modes, improving patient comfort and operational convenience[6]. Market Position and Strategy - The company continues to enhance its marketing efforts, leading to an expanded sales coverage and increased recognition of its blood purification devices in domestic and international hospitals[22]. - The domestic market share of local blood purification equipment manufacturers has increased to approximately 36.3%, up from 32.4% in Q4 2022, while foreign brands hold about 53.3%[29]. - The company is focusing on expanding its market presence through the development of new technologies and products in the blood purification sector[55]. - The company is actively participating in global medical exhibitions to gather potential customer resources and enhance brand awareness[87]. Innovation and Technology - The company has obtained 40 invention patents, including 38 domestic and 2 foreign patents, along with 71 utility model patents and 24 design patents[31]. - The company’s blood purification technology has filled several domestic technical gaps, contributing to its leading position in the industry[32]. - The company has developed a multi-organ support technology that integrates kidney replacement therapy, artificial liver technology, and blood purification treatment, surpassing key technologies in blood purification equipment[53]. - The company has patented multiple technologies, including a blood purification device with automatic pump tube assembly and disassembly, enhancing operational efficiency[54]. - The company has developed specialized components for hemodialysis machines, including pressure relief tanks and liquid level monitoring systems, supported by multiple patents[61]. Risks and Challenges - The company is facing risks related to new product development, including long R&D cycles and high investment costs[90]. - There is a risk of core technical personnel turnover, which could impact R&D and production capabilities[91]. - The company is addressing potential risks related to the quality control of medical devices, which are subject to strict regulatory standards[97]. - The company is exposed to competitive risks in the blood purification equipment and consumables market, where it lags behind leading foreign brands[103]. Environmental Responsibility - The company invested 1.0355 million yuan in environmental protection during the reporting period[131]. - The company has established mechanisms for environmental protection and pollution prevention[131]. - The company has implemented waste gas treatment facilities that meet the secondary standards of the Comprehensive Emission Standard for Air Pollutants[134]. - The company processes wastewater through an on-site treatment station before it enters the municipal sewage system[134]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[139]. Corporate Governance - The company experienced changes in its board of directors, with new appointments including Jiang Feng as an independent director and Kong Lingmin as a non-independent director[125]. - The company has established a policy that limits annual share transfers by insiders to no more than 25% of their total holdings during their tenure[151]. - The company has committed to not transferring or managing shares acquired within 12 months post-IPO, ensuring stability in shareholding[150]. - The company will ensure that any share reduction after the lock-up period complies with relevant laws and regulations, including the Shanghai Stock Exchange rules[153].

重庆山外山血液净化技术股份有限公司 第三届董事会第三次会议资料 重庆山外山血液净化技术股份有限公司 独立董事关于第三届董事会第三次会议 相关事项的独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司独立董事规 则》《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）及《公司章 程》等的相关规定，作为重庆山外山血液净化技术股份有限公司（以下简称"公司"） 的独立董事，公司已在召开董事会前就上述议案具体情况向我们进行了说明，并向 我们提交了相关文件，我们对第三届董事会第三次会议相关议案发表如下独立意见： 一、《关于 2023 年半年度募集资金存放与实际使用情况的专项报告的议案》 经核查，独立董事认为:公司 2023 年半年度募集资金的存放与使用符合中国证 监会、上海证券交易所关于上市公司募集资金存放和使用的相关规定，不存在违反 募集资金管理和使用的相关规定、不存在损害公司及全体股东尤其是中小股东利益 的情形;该议案内容真实、准确、完整，不存在虚假记载、误导性陈述和重大遗漏。 综上所述，公司全体独立董事一致同意董事会出具的公司《2023 年半年度募集 资金存放与实际使用情况的专项报 ...

重庆山外山血液净化技术股份有限公司 2023 年半年度募集资金存放与使用情况鉴证报告 天职业字[2023]40966-1 号 日 录 募集资金存放与使用情况鉴证报告— -1 专项报告 -- 3 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进 重庆山外山血液净化技术股份有限公司 2023 年半年度募集资金存放与实际使用情况鉴证报告 天职业字[2023]40966-1 号 重庆山外山血液净化技术股份有限公司全体股东: 我们审核了后附的重庆山外山血液净化技术股份有限公司(以下简称"山外山")《关于 2023 年半年度募集资金存放与实际使用情况的专项报告》。 一、管理层的责任 山外山管理层的责任是提供真实、合法、完整的相关资料,按照《上市公司监管指引第2号 -上市公司募集资金管理和使用的监管要求(2022年修订)》、《上海证券交易所科创板上 市公司自律监管规则适用指引第1 号 -- 规范运作》及相关格式指引规定编制《关于 2023年半 年度募集资金存放与实际使用情况的专项报告》,并保证其内容的真实、准确、完整,不存在虚 假记载、误导性陈述或重大遗漏。 二、注 ...

重庆山外山血液净化技术股份有限公司 审计报告 天职业字[2023]40966 号 日 录 审计报告 -- -1 财务报表 - -6 财务报表附注 ------ -18 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" 报告编码:京23KMV6 审计报告 天职业字[2023]40966 号 重庆山外山血液净化技术股份有限公司全体股东: 一、审计意见 我们审计了重庆山外山血液净化技术股份有限公司(以下简称"山外山")财务报表,包括 2023年6月30日的合并及母公司资产负债表,2023年1-6月的合并及母公司利润表、合并及 母公司现金流量表、合并及母公司所有者权益变动表,以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 山外山 2023 年 6 月 30日的合并及母公司财务状况以及 2023 年 1-6 月的合并及母公司经营成 果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对财 务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 ...

召开日期时间：2023 年 9 月 12 日 14 点 30 分 证券代码：688410 证券简称：山外山 公告编号：2023-058 重庆山外山血液净化技术股份有限公司 关于召开 2023 年第四次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第四次临时股东大会 召开地点：重庆市两江新区慈济路 1 号 8 楼会议室 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 12 日 至 2023 年 9 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2023年9月12日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系 ...

出席会议的监事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于 2023 年半年度报告及摘要的议案》 监事会认为：公司 2023 年半年度报告编制和审议的程序符合法律、行政法 规及中国证监会的规定，报告内容真实、准确、完整地反映了上市公司的财务状 况和经营成果等事项，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。 证券代码：688410 证券简称：山外山 公告编号：2023-055 重庆山外山血液净化技术股份有限公司 第三届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 重庆山外山血液净化技术股份有限公司（以下简称"公司"）第三届监事会 第三次会议于 2023 年 8 月 25 日（星期五）在重庆市两江新区慈济路 1 号 8 楼会 议室以现场的方式召开。会议通知已于 2023 年 8 月 15 日通过邮件的方式送达各 位监事，本次会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主席秦继 忠主持，公司部分 ...

证券代码：688410 证券简称：山外山 公告编号：2023-056 重庆山外山血液净化技术股份公司 关于 2023 年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求（2022 年修订）》和《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市 规则》等有关规定，重庆山外山血液净化技术股份有限公司（以下简称"公司" 或"本公司"或"山外山"）编制了 2023 年半年度（以下简称"报告期内"） 募集资金存放与实际使用情况的专项报告。具体如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会于 2022 年 11 月 15 日出具的《关于同意重庆 山外山血液净化技术股份有限公司首次公开发行股票的批复》（证监许可〔2022〕 2873 号），同意公司首次公开发行股票的注册申请，并经上海证券交易所同意， 公 ...

证券代码：688410 证券简称：山外山 公告编号：2023-057 重庆山外山血液净化技术股份有限公司 关于 2023 年半年度利润分配及资本公积金 转增股本预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配及资本公积金转增股本预案内容 经天职国际会计师事务所（特殊普通合伙）审计，截至 2023 年 6 月 30 日， 公司 2023 年半年度实现归属于上市公司股东的净利润为人民币 134,240,442.45 元，母公司资本公积金余额 1,340,355,286.00 元，母公司期末可供分配利润为 人民币 241,692,951.32 元；经公司第三届董事会第三次会议决议，公司 2023 年半年度拟以实施权益分派股权登记日登记的总股本为基数进行利润分配及资 本公积金转增股本。 ● 每股分配及转增比例：公司拟向全体股东每 10 股派发现金红利人民币 2.00 元（含税），同时以资本公积金向全体股东每 10 股转增 4.9 股。 ● 本次利润分配及资本公积金转增股本以实施权益分派股权登 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥193,032,111.71, representing a year-on-year increase of 187.14%[5] - Net profit attributable to shareholders was ¥74,586,123.06, a significant increase of 866.83% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥71,078,708.92, reflecting a year-on-year growth of 1,103.68%[5] - Basic and diluted earnings per share were both ¥0.5153, an increase of 624.75% year-on-year[6] - The total operating revenue for Q1 2023 was CNY 193,032,111.71, a significant increase from CNY 67,225,376.61 in Q1 2022, representing a growth of approximately 187.5%[23] - The net profit for Q1 2023 reached CNY 74,198,500.21, a substantial rise from CNY 7,312,622.81 in Q1 2022, reflecting an increase of approximately 907.5%[25] - The total comprehensive income attributable to the parent company for Q1 2023 was ¥74,586,123.06, compared to ¥7,714,539.65 in Q1 2022, representing a significant increase[26] - Basic and diluted earnings per share for Q1 2023 were both ¥0.5153, up from ¥0.0711 in Q1 2022, indicating a substantial improvement in profitability[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,030,520,823.98, an increase of 5.56% from the end of the previous year[6] - As of March 31, 2023, the company's total current assets amounted to RMB 1,862,705,981.47, an increase from RMB 1,756,545,255.66 as of December 31, 2022, representing a growth of approximately 6.05%[18] - The company's total assets as of Q1 2023 amounted to CNY 2,030,520,823.98, up from CNY 1,923,657,055.17 in the previous year, marking an increase of about 5.6%[20] - The total liabilities for Q1 2023 were CNY 440,880,924.65, compared to CNY 408,641,670.42 in Q1 2022, which is an increase of approximately 7.9%[20] Cash Flow - The net cash flow from operating activities was ¥49,621,308.92, reflecting a significant increase in cash received from sales compared to the same period last year[10] - Net cash flow from operating activities for Q1 2023 was ¥49,621,308.92, a turnaround from a negative cash flow of ¥6,188,908.59 in Q1 2022[28] - Cash inflow from operating activities totaled ¥252,235,785.99 in Q1 2023, compared to ¥75,744,422.97 in the same period last year, reflecting a growth of 233%[28] - Cash outflow for operating activities was ¥202,614,477.07 in Q1 2023, compared to ¥81,933,331.56 in Q1 2022, showing an increase of 147%[28] - The company reported a net increase in cash and cash equivalents of ¥20,292,229.89 for Q1 2023, contrasting with a decrease of ¥16,713,855.22 in Q1 2022[28] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was ¥1,488,164,956.19, compared to ¥154,809,279.39 at the end of Q1 2022[28] Research and Development - Research and development expenses totaled ¥6,061,357.91, accounting for 3.14% of operating revenue, down from 5.55%[6] - The company's R&D expenses in Q1 2023 were CNY 5,933,038.80, up from CNY 3,983,811.33 in Q1 2022, indicating a growth of about 48.9%[23] Shareholder Information - The company reported a total of 7,334 common shareholders at the end of the reporting period[12] - The company has identified several key shareholders, with the largest holding being China Industrial Bank Co., Ltd. with 1,384,146 shares[14] Subsidiary Transfers - The company decided to transfer its subsidiary, Chongqing Shanchuan Blood Dialysis Center Co., Ltd., for RMB 4 million due to high operational costs[15] - Another subsidiary, Junlian Kanda Blood Dialysis Center Co., Ltd., was also transferred for RMB 2.5 million, again due to ongoing losses[15] Inventory and Receivables - The company's inventory increased to RMB 180,093,298.00 from RMB 133,686,275.33, marking a rise of about 34.8%[18] - The company reported an increase in accounts receivable to RMB 117,121,708.93 from RMB 116,035,138.39, a slight increase of about 0.93%[18] - The prepayments rose to RMB 22,786,725.80 from RMB 9,787,626.87, showing an increase of approximately 132.5%[18] Financial Activities - The company has not reported any significant changes in its financing and securities business activities during the reporting period[14] - The company is not applying new accounting standards or interpretations for the first time in 2023, ensuring consistency in financial reporting[29]